Clinical significance of genetic influences on cardiovascular drug metabolism.
Inherited differences in metabolism may be responsible for individual variability in the efficacy of drugs and the occurrence of adverse drug reactions. Among the cardiovascular drugs reported to exhibit genetic polymorphism are debrisoquine, sparteine, some beta-adrenoceptor antagonists, flecainide, encainide, propafenone, nifedipine, procainamide, and hydralazine. The implications of genetic differences in the metabolism of these drugs for cardiovascular therapeutics is the subject of this review.
Arcavi
L
L
Division of Clinical Pharmacology and Experimental Therapeutics, San Francisco General Hospital Medical Center, CA 94110.
Benowitz
N L
NL
D000319:Adrenergic beta-Antagonists / Q000378:metabolism*; D000889:Anti-Arrhythmia Agents / Q000378:metabolism*; D000959:Antihypertensive Agents / Q000378:metabolism*; D002121:Calcium Channel Blockers / Q000378:metabolism*; D003577:Cytochrome P-450 Enzyme System / Q000737:chemistry / Q000235:genetics / Q000378:metabolism; D005260:Female; D006801:Humans; D007527:Isoenzymes; D008099:Liver / Q000378:metabolism; D008297:Male; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D007527:Isoenzymes; D003577:Cytochrome P-450 Enzyme System